Material Agreements

Applied Digital Corp. entered into Purchase and Sale Agreement with Mara Garden City LLC valued at $87,328,675.00 purchase price plus $9,971,235 additional consideration (effective 2024-03-14).

“On March 14, 2024, APLD – Rattlesnake Den I LLC (“Rattlesnake Den I”), a Delaware limited liability company and a subsidiary of Applied Digital Corporation, a Nevada corporation (the “Company”), entered into a purchase and sale agreement (the “Purchase and Sale Agreement”) with Mara Garden City LLC (“Mara Garden City”), a Delaware limited liability company and a subsidiary of Marathon Digital Holdings, Inc. (“Marathon”), pursuant to which Rattlesnake Den I agreed to sell to Mara Garden City (the “Transaction”) its data center facility located in Garden City, Texas (the “Facility”) consisting of the ground leasehold estate and interest held under the Ground Lease dated April 13, 2022 between Rattlesnake Den I, as tenant, and EDB, Ltd., a Texas limited liability company, as landlord (the “Ground Lease”), related to approximately 50 acres in Glasscock County, Texas and related tangible and intangible property and improvements (together with the Ground Lease, the “Property”).”

Track Group, Inc. entered into Sales, Licensing, Maintenance, and Services Agreement with Marion County Community Corrections Agency (effective 2024-03-11).

“Track Group, Inc. (the “ Company ”) entered into a new multi-year Sales, Licensing, Maintenance, and Services Agreement (the “ Agreement ”) with Marion County Community Corrections Agency, by and through the Marion County Community Corrections Board (collectively, “ Marion County ”)”

YUNHONG GREEN CTI LTD. entered into Stock Purchase Agreement for Series F Preferred Stock and Series F Investor Warrant with Agile Wisdom International Limited valued at $700,000 (effective 2024-03-11).

“On March 11, 2024, the Company entered into a Stock Purchase Agreement (the “Series F Preferred SPA”) with Agile Wisdom International Limited (the “Series F Investor”), pursuant to which the Company agreed to issue and sell, and the Series F Investor agreed to purchase, 70,000 shares of the Company’s newly created Series F Convertible Preferred Stock (“Series F Preferred”), at a purchase price of $10.00 per share, resulting in gross proceeds to the Company of $700,000”

YUNHONG GREEN CTI LTD. entered into Stock Purchase Agreement for Series E Preferred Stock / Series E Investor Warrant with Wickbur Holdings LLC valued at $1,300,000 (effective 2024-03-11).

“On March 11, 2024, Yunhong Green CTI Ltd. (the “Company”), entered into a Stock Purchase Agreement (the “Series E Preferred SPA”) with Wickbur Holdings LLC (the “Series E Investor”), pursuant to which the Company agreed to issue and sell, and the Series E Investor agreed to purchase, 130,000 shares of the Company’s newly created Series E Convertible Preferred Stock (“Series E Preferred”), at a purchase price of $10.00 per share, resulting in gross proceeds to the Company of $1,300,000”

OLENOX INDUSTRIES INC. entered into Promissory Note with 1800 Diagonal Lending LLC valued at $149,500 (effective 2024-03-05).

“On March 5, 2024, Safe & Green Holdings Corp. (the “Company”) issued a Promissory Note (“Note”) in favor of 1800 Diagonal Lending LLC (the “Lender”) in the aggregate principal amount of $149,500 (the “Principal”), and an accompanying Securities Purchase Agreement, dated March 5, 2024 (the “SPA”).”

OLENOX INDUSTRIES INC. entered into Securities Purchase Agreement with 1800 Diagonal Lending LLC (effective 2024-03-05).

“On March 5, 2024, Safe & Green Holdings Corp. (the “Company”) issued a Promissory Note (“Note”) in favor of 1800 Diagonal Lending LLC (the “Lender”) in the aggregate principal amount of $149,500 (the “Principal”), and an accompanying Securities Purchase Agreement, dated March 5, 2024 (the “SPA”).”

FLAGSTAR BANK, NATIONAL ASSOCIATION amended Reverence Investment Agreement with Reverence Capital Partners L.P. (effective 2024-03-11).

“(“Liberty”), (b) affiliates of funds managed by Hudson Bay Capital Management, LP (“Hudson Bay”), (c) affiliates of funds managed by Reverence Capital Partners L.P. (“Reverence”) and (d) certain other investors (the “Other Investors” and, collectively with Liberty, Reverence and Hudson Bay, the “Investors”, and the investment agreements entered into with each of the Investors on March 7, 2024, collectively, the “Original Investment Agreements”).”

FLAGSTAR BANK, NATIONAL ASSOCIATION amended Hudson Bay Investment Agreements with Hudson Bay Capital Management, LP (effective 2024-03-11).

“(“Liberty”), (b) affiliates of funds managed by Hudson Bay Capital Management, LP (“Hudson Bay”), (c) affiliates of funds managed by Reverence Capital Partners L.P.”

FLAGSTAR BANK, NATIONAL ASSOCIATION amended Liberty Investment Agreement with Liberty 77 Capital L.P. (effective 2024-03-11).

“On March 11, 2024, NYCB entered into separate amendments to the Original Investment Agreements with Liberty (such agreement, as amended, the “Liberty Investment Agreement”)”

FLAGSTAR BANK, NATIONAL ASSOCIATION entered into Investment Agreements with affiliates of funds managed by Liberty 77 Capital L.P., Hudson Bay Capital Management, LP, Reverence Capital Partners L.P., and certain other investors valued at approximately $1.05 billion (effective 2024-03-07).

“the Investors invested an aggregate of approximately $1.05 billion in the Company in exchange for the sale and issuance of: (a) 76,630,965 shares of common stock, par value $0.01 per share, of NYCB (the “Common Stock”) at a purchase price per share of $2.00; (b) 192,062 shares of a new series of preferred stock”

Everforth Inc amended First Amendment to Third Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto valued at $498,750,000 (effective 2024-03-13).

“On March 13, 2024, ASGN Incorporated (the “Company”) entered into a First Amendment to Third Amended and Restated Credit Agreement (the “Amendment”) with Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto.”

CADIZ INC entered into GSWC Agreement with Golden State Water Company (effective 2024-03-13).

“On March 13, 2024, Cadiz Inc. (the “Company” or “Cadiz”) and Fenner Gap Mutual Water Company entered into a water supply agreement with Golden State Water Company (“GSWC”), an investor-owned utility serving the City of Barstow, California (“GSWC Agreement”).”

Avid Bioservices, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $160.0 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (effective 2024-03-12).

“On March 12, 2024, Avid Bioservices, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $160.0 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes were issued pursuant to an indenture, dated March 12, 2024 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”

DELUXE CORP entered into RFA with MUFG Bank, Ltd. valued at $80 million (effective 2024-03-13).

“On March 13, 2024 (the "Closing Date"), Deluxe Receivables LLC ("Borrower"), a special purpose company and wholly-owned subsidiary of Deluxe Corporation (the "Company"), a Minnesota corporation, entered into an accounts receivable financing facility (the "AR Facility") of up to $80 million with MUFG Bank, Ltd., as administrative agent (the "Administrative Agent") pursuant to a receivables financing agreement, dated as of the Closing Date (the "RFA"), among the Borrower, the Company, as servicer (the "Servicer"), the Administrative Agent and the group and agents and lenders party thereto.”

Global Star Acquisition Inc. amended First Amendment to the Merger Agreement with K Enter Holdings Inc. valued at The First Amendment (i) reduces the base value of the merger consideration to be received by Company (effective 2024-03-11).

“On March 11, 2024, the Company, K Enter, Purchaser, and Merger Sub entered into a First Amendment to the Merger Agreement (the "First Amendment") to amend certain of the terms of the Merger Agreement.”

Embrace Change Acquisition Corp. entered into Satisfaction and Discharge of Indebtedness Pursuant to Underwriting Agreement dated August 9, 2022 with EF Hutton LLC valued at $2,587,499 (effective 2024-03-04).

“On March 4, 2024, Embrace Change Acquisition Corp. (the “Company”) and EF Hutton LLC, formerly known as EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”), the underwriter of the Company’s initial public offering, entered into a Satisfaction and Discharge of Indebtedness Pursuant to Underwriting Agreement dated August 9, 2022 (the “Satisfaction and Discharge Agreement”), pursuant to which, EF Hutton agrees to revise the deferred underwriting fee of three point five percent (3.50%) of the gross proceeds of the initial public offering, or $2,587,499, to (1) $750,000 in cash on the date of the closing of the initial business combination (the “Closing”) and (2) 200,000 of registered and unrestricted shares of the Company, shall be issued and delivered to EF Hutton at the Closing.”

PSQ Holdings, Inc. entered into Note Exchange Agreement with Participating Noteholders valued at $8.45 million of Replacement Notes, convertible into shares of Class A Common Stock, bearing interes (effective 2024-03-13).

“An aggregate of $8.45 million of Replacement Notes, convertible into shares of Class A Common Stock, were delivered to participating former holders of Credova subordinated notes and new investors in Credova subordinary notes issued prior to closing (the “Participating Noteholders”).”

PSQ Holdings, Inc. entered into Credova Merger Agreement with Cello Merger Sub, Inc., Credova Holdings, Inc., Samuel L. Paul valued at 2,920,993 newly-issued shares of Class A Common Stock (effective 2024-03-13).

“On March 13, 2024, PSQ Holdings, Inc. (the “Company” or “PSQ”) entered into an agreement and plan of merger (the “Credova Merger Agreement”) with Cello Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (“Merger Sub”), Credova Holdings, Inc., a Delaware corporation (“Credova”), and Samuel L. Paul, in the capacity as the Seller Representative in accordance with the terms of the Credova Merger Agreement.”

AirJoule Technologies Corp. entered into Subscription Agreement (effective 2024-03-08).

“On March 8, 2024, in connection with the Business Combination (as defined below), Power & Digital Infrastructure Acquisition II Corp., a Delaware corporation (“XPDB”) entered into a subscription agreement (the “Subscription Agreement”) with a certain investor (the “PIPE Investor”), pursuant to which, among other things, the PIPE Investor has agreed to subscribe for and purchase from XPDB, and XPDB has agreed to issue and sell to the PIPE Investor, an aggregate of 588,235 newly issued shares of XPDB’s Class A common stock, par value $0.0001 (“Class A Common Stock”) on the terms and subject to the conditions set forth therein.”

Proterra Inc terminated Second Amended and Restated Chapter 11 Plan Support Agreement with Anthelion Prodigy Co-Investment LP, Anthelion I Prodigy Holdco LP, Anthelion PRTA Co-Investment LP, and the Official Committee of Unsecured Creditors.

“that certain Second Amended and Restated Chapter 11 Plan Support Agreement entered into among the Debtors, the Official Committee of Unsecured Creditors appointed in the Chapter 11 Cases and Anthelion Prodigy Co-Investment LP, Anthelion I Prodigy Holdco LP, and Anthelion PRTA Co-Investment LP was automatically terminated pursuant to its terms”

NEXTNRG, INC. entered into Note with Next Charging, LLC ("Next") valued at $165,000 (effective 2024-03-08).

“On March 8, 2024, EzFill Holdings, Inc. (the “Company”) and Next Charging, LLC (“Next”) entered into a promissory note (the “Note”) for the sum of $165,000 (the “Loan”)”

Hess Midstream LP entered into Unit Repurchase Agreement with Hess Investments North Dakota LLC and GIP II Blue Holding, L.P. valued at approximately $100 million (effective 2024-03-11).

“On March 11, 2024, Hess Midstream LP, a Delaware limited partnership (the “Company”), Hess Midstream Operations LP, a Delaware limited partnership and a subsidiary of the Company that holds all of the Company’s operating assets (“HESM OpCo” and, together with the Company, the “Partnership Entities”), Hess Investments North Dakota LLC, a Delaware limited liability company (“HINDL”), and GIP II Blue Holding, L.P., a Delaware limited partnership (“GIP” and, together with HINDL, the “Sponsors” and each, a “Sponsor”), entered into a Unit Repurchase Agreement (the “Repurchase Agreement”) pursuant to which HESM OpCo agreed to purchase from (a) HINDL 1,059,390 Class B units representing limited partner interests in HESM OpCo (the “Class B Units”) and (b) GIP 1,757,511 Class B Units (such Class B Units subject to the Repurchase Agreement, the “Repurchased Units”) for an aggregate purchase price of approximately $100 million (the “Repurchase Transaction”).”

Odyssey Semiconductor Technologies, Inc. entered into Promissory Notes with Nina and John Edmunds 1998 Family Trust valued at a secured convertible promissory note in the amount of $250,000 and a secured convertible promissory (effective 2024-03-14).

“On March 14, 2024, Odyssey Semiconductor Technologies, Inc. (the “Company”) issued a secured convertible promissory note in the amount of $250,000 and a secured convertible promissory note in the amount of $184,000 (the “Promissory Notes”), respectively, to the Nina and John Edmunds 1998 Family Trust dated January 27, 1998 (the “Edmunds Trust”), of which the Company’s Chairman, John Edmunds, is the trustee.”

Unicycive Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Aggregate purchase price of $50 million for 50,000 shares of Series B Convertible Preferred Stock at (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), 50,000 shares of its Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share with an initial conversion price of $1.00 per share, subject to adjustment (the “ Conversion Price”) , for an aggregate purchase price of $50 million.”

Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred””

AppLovin Corp amended Amendment No. 10 with Bank of America, N.A. valued at $1,463,750,000 (effective 2024-03-14).

“On March 14, 2024, AppLovin Corporation (“AppLovin” or “Company”) entered into Amendment No. 10 (“Amendment No. 10”) to that certain Credit Agreement, dated as of August 15, 2018, by and among AppLovin, as borrower, Bank of America, N.A., as administrative agent and collateral agent, and the other parties thereto”

Acushnet Holdings Corp. entered into a equity purchase with Magnus Holdings Co., Ltd. valued at $37.5 million (effective 2024-03-14).

“On March 14, 2024, in connection with its existing $1.0 billion share repurchase authorization, Acushnet Holdings Corp. (the “Company”) entered into an agreement with Magnus Holdings Co., Ltd. (“Magnus”) pursuant to which the Company will purchase up to an aggregate of $37.5 million of shares of its common stock from Magnus on a share-for-share basis as the Company repurchases shares in the open market or privately negotiated transactions.”

Cardlytics, Inc. entered into Agreement with American Express Travel Related Services Company, Inc. (effective 2024-03-14).

“On March 14, 2024, Cardlytics, Inc. (the “Company”) entered into an agreement (the “Agreement”) with American Express Travel Related Services Company, Inc. (“AXP”).”

Phunware, Inc. entered into Settlement Agreement and Release of Claims with Wilson Sonsini Goodrich & Rosati, PC valued at total sum of $2,193,852.02 (effective 2024-03-05).

“On March 5, 2024, the Company entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with WSGR settling the Uber Litigation. As part of the Settlement Agreement, the Company was required to (i) pay WSGR a total sum of $2,193,852.02 no later than March 8, 2024, (ii) file requests for dismissal of the Uber Litigation, with prejudice, with the Santa Clara Superior Court, and (iii) request that the Uber Arbitration be dismissed and closed with prejudice. In addition, WSGR is required to request that the Uber Arbitration be dismissed and closed with prejudice. The Settlement Agreement also provides that the Company and WSGR release each other from all claims that the Company or WSGR may have against one another with respect to the Uber Litigation or the Uber Arbitration. The full text of the Settlement Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.”

Red Rock Resorts, Inc. entered into Indenture with Deutsche Bank Trust Company Americas, as trustee valued at $500 million aggregate principal amount of 6.625% Senior Notes due 2032 (effective 2024-03-14).

“On March 14, 2024, Red Rock Resorts, Inc.’s consolidated subsidiary, Station Casinos LLC (the “Company”), issued $500 million aggregate principal amount of 6.625% Senior Notes due 2032 (the “Notes”) pursuant to an indenture, dated as of March 14, 2024 (the “Indenture”), among the Company, the guarantors party thereto (the “Guarantors”) and Deutsche Bank Trust Company Americas, as trustee.”

Red Rock Resorts, Inc. entered into Credit Agreement with Deutsche Bank AG Cayman Islands Branch, as administrative agent and collateral agent, and the lenders party thereto (effective 2024-03-14).

“On March 14, 2024, the Company, the subsidiary guarantors party thereto, Deutsche Bank AG Cayman Islands Branch, as administrative agent and collateral agent, and the lenders party thereto entered into an Amended and Restated Credit Agreement (the “Credit Agreement”), which amended and restated the Existing Credit Agreement and pursuant to which the Company (a) incurred (i) a new senior secured term “B” loan facility in an aggregate principal amount of $1,570.0 million (the “New Term B Facility” and the term “B” loans funded thereunder, the “New Term B Loan”) and (ii) a new senior secured revolving credit facility in an aggregate principal amount of $1,100.0 million (the “New Revolving Credit Facility” and, together with the New Term B Facility, the “New Credit Facilities”)”

PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).

“Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.”

PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe”

PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share”

PAVmed Inc. amended Amendment and Waiver with holder of senior secured convertible notes valued at $2,000,000 cash payment; maturity extended to April 4, 2025 (April 2022 Note) and September 8, 2025 (effective 2024-03-12).

“Effective as of March 12, 2024, PAVmed Inc. (the “ Company ”), entered into an amendment and waiver (the “ Amendment and Waiver ”) with the holder of the senior secured convertible note issued by the Company as of April 4, 2022 (the “ April 2022 Note ”) and the secured convertible note issued by the Company as of September 8, 2022 (the “ September 2022 Note ,” and together with the April 2022 Note, the “ Notes ”).”

GridAI Technologies Corp. entered into Merger Agreement with ImmunogenX.

“Pursuant to the terms of the Merger Agreement, we are required to recommend that our stockholders approve the conversion of shares of our Series G Preferred Stock into shares of our Common Stock.”

Oportun Financial Corp entered into Amendment No. 3 to the Credit Agreement (Third Amendment) with certain affiliates of Neuberger Berman Specialty Finance as lenders, and Wilmington Trust, National Association, as administrative agent and collateral agent valued at Modifies minimum asset coverage ratio covenant levels, provides for an interest rate step-up of 3.00 (effective 2024-03-12).

“On March 12, 2023, the Company entered into an Amendment No. 3 to the Credit Agreement (the “Third Amendment”), by and among the Company, as borrower, the subsidiaries of the Company party thereto as guarantors, certain affiliates of Neuberger Berman Specialty Finance as lenders, and Wilmington Trust, National Association, as administrative agent and collateral agent (the “Agent”), which amended the Credit Agreement, dated as of September 14, 2022, as amended, by and among the Company, the lenders from time to time party thereto and the Agent.”

Oportun Financial Corp entered into Eighth Amendment to the Indenture (Eighth RF Indenture Amendment) with Wilmington Trust, National Association valued at Provides for a three-month principal payment holiday for March, April and May 2024 in amounts equal (effective 2024-03-08).

“On March 8, 2024, Oportun RF, LLC (the “RF Issuer”), a subsidiary of Oportun Financial Corporation (the “Company”), and Wilmington Trust, National Association, as indenture trustee, securities intermediary and depositary bank, entered into the Eighth Amendment to the Indenture (the “RF Indenture”) dated December 20, 2021 (the “Eighth RF Indenture Amendment”), and other related documents (together with the Eighth RF Indenture Amendment, the “Eighth RF Amendment”) related to the Company’s asset-backed variable funding facility secured by certain residual cash flows from the Company’s securitizations.”

Rezolute, Inc. entered into Exchange Agreement with certain Company stockholders valued at aggregate of 3,000,000 shares of common stock (effective 2024-03-08).

“On March 8, 2024, Rezolute, Inc. (the “Company”) entered into a securities exchange agreement (the “Exchange Agreement”) with certain Company stockholders (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 3,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Retired Shares”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 3,000,000 shares of common stock”

Regulus Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at total gross proceeds of approximately $100.0 million (effective 2024-03-11).

“On March 11, 2024, Regulus Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company sold and issued (i) 45,108,667 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $1.60 per share and (ii) 173,915 shares of the Company’s newly designated non-voting Class A-6 convertible preferred stock, par value $0.001 per share (the “Class A-6 Convertible Preferred Stock”), in lieu of shares of Common Stock, at a purchase price of $160.00 per share in a private placement transaction (the “Private Placement”), which closed on March 14, 2024 (the “Closing”).”

OptiNose, Inc. entered into Manufacturing and Supply Agreement with Hikma Pharmaceuticals USA, Inc. valued at Manufacturing and Supply Agreement for XHANCE units; minimum purchase obligations; term through Dece (effective 2020-12-11).

“OptiNose, Inc. (“Optinose”) and Hikma Pharmaceuticals USA, Inc. (“Hikma”) are parties to a Manufacturing and Supply Agreement, dated December 11, 2020 (the “Manufacturing Agreement”) pursuant to which, following FDA approval of Hikma as an alternative manufacturing site (which occurred on March 9, 2024), Hikma will manufacture and supply finished XHANCE units.”

Vita Coco Company, Inc. entered into Manufacturing Agreement with Century Pacific Food, Inc. (effective 2024-03-08).

“On March 8, 2024, All Market Singapore PTE Ltd., a wholly owned subsidiary of The Vita Coco Company, Inc. (the “Company”), entered into a Manufacturing and Purchasing Agreement (the “Manufacturing Agreement”) with Century Pacific Food, Inc. (“Century Pacific”).”

Cartesian Therapeutics, Inc. terminated License and Development Agreement with Audentes Therapeutics, Inc. ("Astellas") (effective 2024-06-06).

“On March 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) received notice from Audentes Therapeutics, Inc. (“Astellas”) of Astellas’ termination of the License and Development Agreement, dated January 8, 2023, by and between the Company and Astellas (the “Agreement”).”

Pacific Oak Strategic Opportunity REIT, Inc. entered into Purchase and Sale Agreement and Joint Escrow Instructions with KB Home Las Vegas, Inc. and Tri Pointe Homes Nevada, Inc. valued at approximately $195 million (effective 2024-03-10).

“On March 10, 2024, Pacific Oak Strategic Opportunity REIT, Inc. (the “Company”), through two indirectly wholly-owned subsidiaries, entered into a Purchase and Sale Agreement and Joint Escrow Instructions (the “Agreement”) for the sale of 454.31 gross acres of land (“Village 2”) located in the City of North Las Vegas, Nevada to KB Home Las Vegas, Inc. and Tri Pointe Homes Nevada, Inc. (collectively, the “Buyer”), subject to certain closing conditions.”

Stablecoin Development Corp entered into Membership Unit Purchase Agreement with New Age Investments LLC valued at $1,070,000 (effective 2024-03-12).

“On March 12, 2024, NovaBay Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Membership Unit Purchase Agreement (the “ Purchase Agreement ”) by and among: (i) New Age Investments LLC, a Florida limited liability company (the “ Buyer ”); (ii) DERMAdoctor, LLC, a Missouri limited liability company (“ DERMAdoctor ”); and (iii) the Company.”

BlackRock Finance, Inc. entered into Indenture with The Bank of New York Mellon valued at $500,000,000 aggregate principal amount of 4.700% Notes due 2029, $1,000,000,000 aggregate principal (effective 2024-03-14).

“The Notes were issued under the Indenture, dated as of March 14, 2024 (the "Base Indenture"), among BlackRock Funding, BlackRock and The Bank of New York Mellon, as trustee (the "Trustee"), as amended by the First Supplemental Indenture, dated as of March 14, 2024, among BlackRock Funding, BlackRock and the Trustee (the "First Supplemental Indenture" and together with the Base Indenture, the "Indenture").”

BlackRock Capital Investment Corp amended First Amendment with the Noteholders (effective 2024-03-13).

“On March 13, 2024, BlackRock Capital Investment Corporation (the “ Company ”) entered into a first amendment (the “ First Amendment ”) to the Master Note Purchase Agreement, dated April 21, 2022”

LKQ CORP entered into Indenture with U.S. Bank Trust Company, National Association, as trustee, and Elavon Financial Services DAC, as paying agent valued at €750,000,000 aggregate principal amount (effective 2024-03-13).

“On March 13, 2024, LKQ Dutch Bond B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of The Netherlands (“LKQ Finance”), an indirect wholly-owned subsidiary of LKQ Corporation (the "Company," "we," "us," or "our"), completed an offering (the “Offering”) of €750,000,000 aggregate principal amount of LKQ Finance’s 4.125% Notes due 2031 (the “Notes”).”

ESSEX PORTFOLIO LP entered into 5.500% Senior Notes due 2034 Indenture with U.S. Bank Trust Company, National Association valued at $350,000,000 (effective 2024-03-14).

“On March 14, 2024, Essex Portfolio, L.P. (the “Operating Partnership”), the operating partnership of Essex Property Trust, Inc. (the “Company”), issued $350.0 million aggregate principal amount of its 5.500% senior notes due 2034 (the “Notes”).”

Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).

“entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).”